Adage and Pfizer knock up Amplyx’s series C to top $90 million Kumar Jeetendra | May 20, 2020 Amplyx Pharmaceuticals, a biotech organization creating imaginative treatments for incapacitating and perilous sicknesses in patients with traded off insusceptible frameworks, today reported that it has shut a $53 million Series C augmentation, which brings the Series C round to over $90 million. The financing was driven by Sofinnova Investments, with support from existing speculators including …
